Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: SyneuRx International (Taiwan) Corp Clear all
Terminated Phase 2Phase 3 Interventional

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

NCT01908192
View directory record Official record
Conditions
Schizophrenia
Interventions
NaBen®, Placebo
Drug
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
20
States / cities
Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 7, 2026, 2:29 AM EDT
Not listed Phase 2 Interventional

Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19

NCT04911777
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Pentarlandir™ UPPTA, Placebo
Drug
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
18 Years to 64 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Cullman, Alabama • Gilbert, Arizona • Bradenton, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 7, 2026, 2:29 AM EDT
Terminated Phase 2Phase 3 Interventional

Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults

NCT02261519
View directory record Official record
Conditions
Schizophrenia
Interventions
NaBen®, Placebo
Drug · Other
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
18 Years to 45 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 7, 2026, 2:29 AM EDT
Recruiting Phase 2Phase 3 Interventional

An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

NCT03094429
View directory record Official record
Conditions
Refractory Schizophrenia
Interventions
NaBen®, Placebo
Drug · Other
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
18 Years to 55 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 7, 2026, 2:29 AM EDT